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7 CURRENTOPINION Management of fever and neutropenia in paediatric
cancer patients: room for improvement? Copyright 
www.co-infectiousdiseases.coma,b,c d eGabrielle M. Haeusler , Lillian Sung , Roland A. Ammann , and
Bob Phillipsf,gPurpose of review
Fever and neutropenia is the most common complication in the treatment of childhood cancer. This review
will summarize recent publications that focus on improving the management of this condition as well as
those that seek to optimize translational research efforts.
Recent findings
A number of clinical decision rules are available to assist in the identification of low-risk fever and
neutropenia however few have undergone external validation and formal impact analysis. Emerging
evidence suggests acute fever and neutropenia management strategies should include time to antibiotic
recommendations, and quality improvement initiatives have focused on eliminating barriers to early
antibiotic administration. Despite reported increases in antimicrobial resistance, few studies have focused
on the prediction, prevention, and optimal treatment of these infections and the effect on risk stratification
remains unknown. A consensus guideline for paediatric fever and neutropenia research is now available
and may help reduce some of the heterogeneity between studies that have previously limited the translation
of evidence into clinical practice.
Summary
Risk stratification is recommended for children with cancer and fever and neutropenia. Further research is
required to quantify the overall impact of this approach and to refine exactly which children will benefit
from early antibiotic administration as well as modifications to empiric regimens to cover antibiotic-resistant
organisms.
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In children with cancer, fever and neutropenia is the
leading cause of emergencydepartment presentation
and unplanned hospital admission [1,2
&
]. Manage-
ment traditionally involves admission to hospital for
intravenous antibiotics until resolution of fever and
recovery of neutrophil count. However, children
with fever and neutropenia are a heterogeneous
groupwith varying risk of severe infection ormedical
complications and this treatment approach is
increasingly recognized as excessive for low-risk epi-
sodes [3]. Clinical decision rules (CDRs) are available
to assist in risk stratification although few centres
have adopted these into routine practice [4,5].
Furthermore, most have focused on the identifi-
cation of low-risk fever and neutropenia and little
is available to assist in the early recognition of con-
ditions associated with significantly higher morbid-
ity and mortality, such as severe sepsis and infection
with antimicrobial-resistant organisms. Given the© 2015 Wolters Kluwer clear differences in infection risk and outcome, and
availability of risk-adaptive algorithms, the standard
of care should move from the ‘one-size-fits-all’ to a
more personalized model taking into account anHealth, Inc. All rights reserved.
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KEY POINTS
 CDRs are available to assist in the risk stratification of
children with fever and neutropenia; however, the true
clinical, psychosocial, and economic impact of this
model of care is unknown.
 Antibiotic administration within 60min has been shown
to improve outcome, although further research is
required to quantify the impact in high and low-
risk cohorts.
 Infection with antibiotic-resistant bacteria is associated
with poor outcome and strategies to predict and
optimize management of this emerging threat are
urgently required.
 A consensus guideline for paediatric fever and
neutropenia research is available and may help reduce
some of the heterogeneity between studies that limit our
interpretation and implementation of results.
Management of fever and neutropenia in paediatric cancer patients Haeusler et al.individual’s probability of infection, sepsis, and
response to treatment.
Risk stratification is the standard of care in the
treatment of many paediatric malignancies. Risk-
adapted treatment intensity based upon extent of
disease, molecular markers, and response to therapy
is thought to be an important contribution to
improvements in 5-year survival to around 80%
[6]. Detailed algorithms guide when to start and
stop a treatment, as well as provide options for poor
response, or ‘resistance’ to standard therapy. Despite
these innovations in cancer treatment, similarly
sophisticated fever and neutropenia treatment
algorithms are not available. This is however, not
for want of trying, as there has been an extensive
quantity of research focused on the cause, biology,
risk factors, prevention, and treatment for fever and
neutropenia in children [7]. Unfortunately, because
of inconsistencies in outcomes that are collected
and reported, our ability to compare, contrast,
and combine results is limited and may, in part,
explain why some advances in fever and neutrope-
nia research have not been translated into practice.
This review will summarize publications, since
2013, that focus on improving the management of
fever and neutropenia in children with cancer. A
review of publications prior to 2013 is available
elsewhere [8].METHODS
MEDLINE was searched via the PubMed interface
using the search terms [(fever or febrile) and (neu-
tropenia or neutropenic) and (child or children or
pediatric or paediatric)] and restricted to articles Copyright © 2015 Wolters Kluwe
0951-7375 Copyright  2015 Wolters Kluwer Health, Inc. All rights resepublished since 1 January 2013. The search date
was 31 May 2015. A total of 249 articles were
screened and 16were included exploring the follow-
ing themes: standardizing paediatric fever and
neutropenia research [7,9
&&
]; defining fever and neu-
tropenia [9
&&
,10
&
]; risk stratification [3,11,12
&&
,13];
and time to antibiotics [14
&
,15
&
,16–21]. Recent
publications addressing the emerging threat of
antibiotic resistance and its relevance to children
with fever and neutropenia are also discussed
[22,23,24
&
,25,26].STANDARDIZING PAEDIATRIC FEVER AND
NEUTROPENIA RESEARCH
A consensus set of core variables and outcomes that
should be measured and reported, as a minimum, in
all paediatric fever and neutropenia studies is now
available [9
&&
]. This is the first time a paediatric-
specific fever and neutropenia research framework
has been developed [7]. The authors hypothesize
that its application will reduce heterogeneity
between clinical studies, limit the impact of report-
ing bias, and lead to research that is more likely to
have outcomes that are relevant to healthcare pro-
viders and to patients and their families. Using the
Delphi method, a 45-member international panel
of clinicians, pharmacists, researchers, and patient
representatives completed four sequential surveys
exploring core outcomes and definitions specific to
paediatric fever and neutropenia research. With a
response rate of up to 96%, consensus was achieved
on a set of eight core variables and 10 core outcomes
as outlined in Table 1. Consensus was also achieved
on definitions for the 10 core outcomes.DEFINING FEVER AND NEUTROPENIA
A consensus definition for ‘fever’ and ‘neutropenia’
was unable to be achieved using the Delphi method
[9
&&
], which is not surprising given the variety differ-
ent definitions that are used in both clinical and
research settings. Regarding fever, 32% of theDelphi
panel agreed with the definition ‘a temperature
greater than 38.58C (101.38F) once or greater than
38.08C (100.48F) on two or more occasions during a
12-h period.’ Agreement for three other commonly
used definitions ranged from 14 to 19% and a fur-
ther three definitions were proposed. Agreement for
a ‘neutropenia’ definition was slightly higher, with
51% in favour of ‘an absolute neutrophil count
less than 500/mm3 or greater than 500 but less
than 1000/mm3 with expected decline to less than
500/mm3 in the next 48h.’
Moving from expert opinion to evidence, there
is only one prospective study that has addressed the
clinical impact of varying definitions for feverr Health, Inc. All rights reserved.
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Table 1. Core variable and outcome set that should be
measured and reported in all paediatric fever and
neutropenia studies (refer to original paper for
corresponding definitions) [9&&]
Core variable set
Age
Diagnosis
Disease status
Chemotherapy intensity
Antibacterial and antifungal prophylaxis
Central venous catheter
Prior stem cell transplant
Core outcome set
Bacteremia
Clinically documented infection
Microbiologically documented infection
Unexplained fever
Sepsis, severe sepsis, and/or septic shock
ICU admission
Serious medical complication
Infection-related mortality
All cause 30-day mortality
Relapse of primary infection
 2014 Wiley Periodicals, Inc.
Antimicrobial agents: bacterial/fungal[10
&
]. In this single-centre study routinely using a
definition of 39.08C, the virtual application of a
lower limit (37.5–38.98C) led to earlier fever and
neutropenia diagnosis (median, 4.5h), and to 53
additional fever and neutropenia diagnosed. In 51
(96%) of these additional episodes, spontaneous
defervescencewithout specific therapywas observed
in reality. The study was not powered to assess the
question of safety of the 39.08C fever definition, and
it is unclear how these single-centre results translate
to other centres and if, or how, they should inform a
consensus definition.RISK STRATIFICATION
The incorporation of a validated and robust paedi-
atric fever and neutropenia CDR into practice Copyright © 2015 Wolters Kluwer 
Derivation study 
(Level 4)
Internal validation
(Level 3)
FIGURE 1. Evidence-based medicine working group stages of c
evidence). Adapted from [12&&].
534 www.co-infectiousdiseases.comshould enable children to receive more or less
intense a high-risk CDR therapy according to their
risk of severe infection or other adverse outcomes.
An overview of risk stratification, including a
review of the efficacy and safety of outpatient
management and oral antibiotic administration
for low-risk fever and neutropenia, is available
[3]. The review discusses potential benefits of
reduced intensity treatment for low-risk patients,
including improved quality of life for the child
and their family, decreased treatment-related
toxicities, and reduced exposure to nosocomial
infections, including multiresistant organisms
as well as considerably reduced health costs.
Although not specifically addressed in this review,
children identified as high risk may benefit from
early and targeted additional supportive care
measures and heightened vigilance so as to avoid
clinical deterioration and ICU admission.
In 2012, an international paediatric fever and
neutropenia guideline panel recommended that
centres adopt a validated risk stratification strategy
and incorporate it into routine clinicalmanagement
(level 1C) [27]. Since publication of this guideline, as
well as an updated systematic review in 2012 that
identified a total of 25 paediatric fever and neutro-
penia CDRs, no new rule has been formally derived
[28]. However, validation of a high-risk CDR [11], a
review of methodological quality of 12 existing
CDRs [12
&&
], and a study investigating an individual
risk factor identified in previously published CDRs
are recently available [13].
A CDR is a clinical tool that quantifies the
individual contributions that various components
of the history, physical examination, and laboratory
results make toward the diagnosis, prognosis, or
likely response to treatment. Although there are
four key components to CDR development
(Fig. 1), most investigators stop short at internal
validation (i.e., in the same population as the
derivation study) resulting in the publication of
CDRs with overestimated diagnostic performance
[12
&&
,28]. Before a CDR can be implemented into
practice it must undergo evaluation in a population
external to the original derivation data set to ensure
it is well tolerated, reliable, and reproducible. Once
we know a CDR accurately predicts outcome, formalHealth, Inc. All rights reserved.
External validation
(Level 2)
Implementation &
impact analysis 
(Level 1)
linical decision rule development (and corresponding level of
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impact of the rule, be it clinical, psychosocial, or
economic, and may even help drive uptake and
sustainability.
The methodological quality of CDRs intended
to identify low-risk fever and neutropenia and
influence management has recently been assessed
in a systematic review [12
&&
]. Seventeen criteria
recommended by the evidence-based medicine
working group were used to analyse 12 CDRs. The
authors summarized these criteria into six key com-
ponents necessary to achieve the highest level of
evidence, including prospective study design;
reproducible external to derivation study; clearly
defined predictive variables; well defined, clinically
significant, and reproducible outcomes; statistical
methods described; and the rule must be clinically
sensible. Results highlight variable compliance
withmethodological criteria for CDRdevelopment.
Notably, the criteria met least often were that the
rule ‘made clinical sense’ and that the variables
and the CDRs were ‘reproducible.’ Only one CDR,
developed in South America, met all methodo-
logical criteria. It is also the only rule that has
undergone prospective medico-economic impact
analysis, and was therefore assigned level I
evidence. Unfortunately, this rule was not reprodu-
cible in Europe, so its clinical utility outside South
America is unclear [12
&&
].
An additional validation study of a CDR
designed to predict severe sepsis not clinically
apparent during the first 4h of hospitalization in
children with fever and neutropenia has been
published [11]. Unlike the majority of fever and
neutropenia CDRs that have focused on the identi-
fication of children at low risk of severe infection,
this rule seeks to predict severe sepsis in high-risk
fever and neutropenia, and is the first time such
a rule has been validated. Factors identified in
the derivation study that were independently
associated with late onset severe sepsis (including
age >12 years, serum C-reactive protein >90mg/l,
and IL-8>200pg/ml) remained significant in the
validation set. However, there was a wide difference
in ability of all three factors to predict severe sepsis
(46% in validation versus 76% in derivation).
Furthermore, as the validation population was from
the same unit as the derivation set, it is unclear how
these results translate to other centres.
There are two fever and neutropenia CDRs that
include haemoglobin as a predictor of outcomewith
conflicting results [28]. In Switzerland, high haemo-
globin (>90g/l) independently predicted severe bac-
terial infection, while in Brazil, low haemoglobin
(<70g/l) independently predicted severe infectious
complications [13]. The unexpected association Copyright © 2015 Wolters Kluwe
0951-7375 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseidentified in the former study was recently subject
to further analysis [13]. The authors concluded that
dehydration, but not medical complications requir-
ing recent transfusion (such as haemolysis, blood
loss, suppressed erythropoiesis, and acute trans-
fusion reaction), contributed to the higher than
expected haemoglobin levels observed in patients
with severe infection. They also found that the
association was U-shaped with moderate anaemia
associated with the lowest risk of severe infection,
whereas both severe anaemia (indicative of severe
myelosuppression) and mild/no anaemia (perhaps
indicative of dehydration) were associated with a
higher risk. These results extend our understanding
of ability of haemoglobin to predict outcome as well
as the potential impact of external factors such as
dehydration on validity of results.TIME TO ANTIBIOTICS
In addition to predicting the risk of adverse events,
recent work has addressed simple modifications in
practice that have the potential to improve overall
results. There are two studies in children with fever
and neutropenia that investigate the impact of time
to antibiotics (TTA) on clinical outcome, both of
which are from high-income countries [14
&
,15
&
]. In
a retrospective study in North America, 29.9% of
children with TTA greater than 60min were admit-
ted to the ICU compared with 12.6% in the TTA less
than 60-min cohort (P¼0.003) [15&]. The study also
showed a nonsignificant trend toward higher
mortality in children who were administered anti-
biotics after 60min. There was no difference in
hospital length of stay (LOS). In a larger North
American study, albeit also retrospective, TTA
greater than 60min was significantly associated
with ‘adverse outcome,’ a composite measure
defined as in-hospital mortality, admission to ICU
or 40ml/kg fluid bolus requirement within 24h of
presentation [14
&
].
No paediatric fever and neutropenia study has
investigated the effect of TTA according to severity
of presenting symptoms, or stratified children
according to risk of severe infection or serious
medical complication. Outside of fever and neutro-
penia, the data for TTA are most convincing in the
setting of severe sepsis with results of a landmark
study in adult patients revealing every hour of delay
in antibiotic administration was associated with an
average decrease in survival of 7.6% [29]. Based on
this, it is conceivable that children with high-risk
fever and neutropenia would benefit most from
early therapy, although further research is required
to quantify the impact of TTA in high and low-
risk cohorts.r Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com 535
Antimicrobial agents: bacterial/fungalA target TTA of 60min for children presenting
with fever and neutropenia has been adopted as a
standard of care inmany centres, although few have
managed to consistently achieve this. There has
been one audit [16] and six quality improvement
initiatives [15
&
,17–21] published since 2013
addressing the issue. Baseline data from the quality
improvement initiatives revealed that the pro-
portion of patients that received antibiotics within
the recommended 60min ranged from 2 to 63%,
with median TTA as high as 154min in one study
[18,20]. Using mixed methodology, including audit
and focus group meetings, four studies identified
specific barriers to timely administration of anti-
biotics (Table 2), the most common of which was
a delay in accessing the central line [15
&
,17,19,21].
Published interventions designed to reduce
TTA in children with fever and neutropenia
presenting to the emergency department are
summarized in Table 2. Following implementation
of various combinations of these interventions, a
significant reduction in TTA was observed across
all studies [15
&
,17–21]. The coordinated efforts of
multidisciplinary teams, standardized fever and Copyright © 2015 Wolters Kluwer 
Table 2. Barriers to time to antibiotics <60min and
corresponding interventions
Barriers Interventions
Recognition of
FN
Standardized triage category and treatment
pathway for all children with cancer
presenting with fever
Patients alert card to notify staff they are at
risk of FN and/or have a central line
CVAD access ED staff education:
CVAD access practical skills workshop
and written and online resources
Patient/family education:
Apply topical anesthetic cream to Port
prior to leaving home
Allow the ED staff to obtain CVAD access
rather than requesting specific oncology
nurses
Ordering blood
tests
Standardized pathology order set for all FN
patients
Nurse initiated CVAD access and blood
tests
Antibiotic
availability
All FN antibiotic options available in the ED
Preprepared antibiotics at set doses
available in ED
Antibiotic
administration
First dose antibiotic prior to CBC result and
oncology consult
Nurse-initiated antibiotics
CBC, cell blood count; CVAD, central venous access devices; ED emergency
department; FN, fever and neutropenia. Adapted from [17,20–23,24
&
].
536 www.co-infectiousdiseases.comneutropenia triage systems and management
algorithms, and comprehensive staff and patient
education campaigns were acknowledged as key
drivers of change. Three algorithms recommended
antibiotic administration prior to neutropenia
confirmation in an attempt to eliminate antibiotic
prescription delay [17–19], with only one study
describing a coordinated approach with the labora-
tory to achieve complete blood count analysis in
as early as 10min [15
&
]. The latter avoiding the
unnecessary administration of antibiotics to non-
neutropenic patients, which was as high as 52% in
one study [19].ANTIBIOTIC RESISTANCE
Infection with antibiotic-resistant bacteria has
emerged as a serious threat to children with fever
and neutropenia [22,23]. Of particular concern are
multidrug-resistant bacteria that render the com-
monly prescribed empiric fever and neutropenia
antibiotics ineffective. Although there are no
recently published studies that have investigated
the clinical impact of antibiotic-resistant infection,
earlier reports indicate these infections do nega-
tively impact prognosis. In particular, a significant
association with prolonged hospital LOS, ICU LOS,
and ventilation requirements has been described
[24
&
,25]. Antibiotic resistance has also been shown
to increase the risk of infection-related and all-cause
mortality [24
&
,30,31]. The rates quoted in some of
these studies were as high as historic reports of
mortality in patients with cancer treated prior to
the routine availability and use of empiric anti-
biotics for fever and neutropenia [32].
In a review of factors associated with antibiotic-
resistant Gram-negative bacteremia, hospital admis-
sion for at least 48h was shown to be significant
[24
&
]. Although the review identified only one
paediatric study that showed recent antibiotic
exposure was also an independent risk factor for
antibiotic-resistant bacteremia, the association is
well described in the adult haematology and
oncology population [33]. Furthermore, in three
studies, the proportion of gram-negative bacteria
resistant to empiric antibiotic regimen used at each
centre increased significantly over time and may, in
part, be explained by repeated exposure to these
agents.
In an era of increasing antimicrobial resistance,
it is incumbent on institutions that offer curative
cancer treatments to similarly offer strategies to
monitor, prevent, and appropriately manage these
infections. At a minimum, local epidemiology and
resistance rates should guide empiric antibiotic
selection as outlined in a recent Italian study [23].Health, Inc. All rights reserved.
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Management of fever and neutropenia in paediatric cancer patients Haeusler et al.A comprehensive review of the current infection-
control issues facing patients with haematological
malignancy is available. The authors of this review
summarize the latest recommendations for infec-
tion control bundles of care as well as antibiotic
options for multidrug-resistant bacteria [26]. The
importance of integrated multidisciplinary antimi-
crobial stewardship (AMS) programmes is also
emphasized with a practical framework for imple-
mentation, based on guidelines from the Fourth
European Conference on Infections in Leukaemia
(ECIL-4), described. Clinical outcome data of the
benefits of AMS are beginning to emerge with a
study in adults showing patients with fever and
neutropenia treated according to AMS recommen-
dations had a relative risk reduction in 28-day
mortality of 64% compared with cases receiving
antimicrobial treatment nonadherent to AMS
recommendations [34].
No paediatric study has specifically addressed
the clinical impact of modifications to empiric fever
and neutropenia antibiotic based on underlying risk
of infection with antibiotic-resistant bacteria. Given
the association with poor outcome, this is an area
where further research is urgently required.CONCLUSION
A risk-stratified approach to care is recommended
for children with fever and neutropenia. Although
many CDRs are available to assist in risk stratifica-
tion, further research is required to refine exactly
which children would benefit most from emerging
management strategies such as target TTA. In the
era of increasing antimicrobial resistance and pauc-
ity of new antibiotic agents in the pipeline, research
should also be directed toward the early predication
and prevention of antibiotic-resistant infections,
and management algorithms adapted according to
local epidemiology. Finally, to encourage uptake
and sustainability of a risk-adapted model of care
for childrenwith fever and neutropenia, the clinical,
psychosocial, and economic impact of currently
available CDRs should be formally investigated
using a recommended research framework
[9
&&
,12
&&
].
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